Choosing the Genetics of Our Children: Options for Framing Public Policy by Kelly, Girard
Santa Clara High Technology Law Journal
Volume 30 | Issue 2 Article 4
January 2013
Choosing the Genetics of Our Children: Options
for Framing Public Policy
Girard Kelly
Follow this and additional works at: http://digitalcommons.law.scu.edu/chtlj
Part of the Intellectual Property Law Commons, and the Science and Technology Law Commons
This Comment is brought to you for free and open access by the Journals at Santa Clara Law Digital Commons. It has been accepted for inclusion in
Santa Clara High Technology Law Journal by an authorized administrator of Santa Clara Law Digital Commons. For more information, please contact
sculawlibrarian@gmail.com.
Recommended Citation
Girard Kelly, Choosing the Genetics of Our Children: Options for Framing Public Policy, 30 Santa Clara High Tech. L.J. 303 (2014).
Available at: http://digitalcommons.law.scu.edu/chtlj/vol30/iss2/4
KELLY  4/2/2014 11:02 PM 
 
303 
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Girard Kelly† 
 
Abstract 
This paper examines the controversial topic of choosing our 
children’s genes through human germ-line manipulation otherwise 
known as Inheritable Genetic Modification (IGM) with current 
Assisted Reproductive Technologies (ARTs) and future Reproductive 
Genetic Biotechnologies (RGBs) such as genetic engineering. The 
purpose of the paper is to examine these potentially revolutionary 
biotechnologies and the emerging social, and bioethical perspectives 
advanced by both proponents and opponents—in the context of the 
legal and regulatory policies impacting ARTs and RGBs. Lastly, the 
paper recommends new public policy and regulatory frameworks to 
support future research and development of RGBs by providing 
legislative guidance to policymakers to ensure responsible oversight. 
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INTRODUCTION 
As research and development continues to advance humankind’s 
understanding of the human genome, our biology, and ultimately our 
biological potential as a species, new biotechnologies will emerge that 
may soon enable parents to choose the future genetics and traits of 
their children.  Normal sexual reproduction supports genetic variation 
in gametes, expressed through changes in alleles located at specific 
locations on the chromosome that pass dominant traits from parent to 
offspring.
1
  This process of Mendelian inheritance is expressed in two 
laws: the Law of Segregation and the Law of Independent 
Assortment, whereby each of the 46 chromosomes segregates during 
meiosis, each with a 50 percent chance of segregating to a particular 
cell.
2
  These fundamental principles of classical genetics frame 
Humankind’s pragmatic abstraction of evolution—that genetic 
determinism produces children born with distinct biological 
advantages or desired phenotypic traits.  Proponents of genetic 
engineering technologies argue that if pursued, such advancements 
could one day enable parents to choose the genes of their children, 
and if presented with the opportunity, humankind should seize control 
of its own destiny.
3
  Humanity, according to such proponents, should 
transcend the draconian and arguably prehistoric practice of random 
genetic variation through sexual reproduction and natural selection to 
begin a new era of human self-design.  This ideology is predicated on 
the belief that Humankind is running twenty-first century software 
(our knowledge) on Stone Age hardware (our bodies) that have not 
changed in the last 50,000 years.
4
 
However, opponents of genetic engineering technologies argue 
that biologically altering humankind is such a radical choice, that its 
consequences could have the potential to destroy humanity itself, 
leaving behind an unrecognizable species, far removed from 
morality.
5
  This ideology advanced by opponents emphasizes several 
 
 1. See CECIE STARR ET AL., BIOLOGY: THE UNITY AND DIVERSITY OF LIFE 154-200 
(12th ed. 2009). 
 2. See id. at 156-57, 173-74. 
 3. See GREGORY STOCK, REDESIGNING HUMANS: CHOOSING OUR GENES, CHANGING 
OUR FUTURE 2 (2003). 
 4. See SURVIVING PROGRESS (Cinemaginaire and Big Picture Media Corporation, in 
Coproduction with the National Film Board of Canada 2012). 
 5. See PRESIDENT’S COUNCIL ON BIOETHICS (U.S.), REPRODUCTION AND 
RESPONSIBILITY: THE REGULATION OF NEW BIOTECHNOLOGIES xii (2004) [hereinafter 
REPRODUCTION AND RESPONSIBILITY]. 
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issues including: the safety risks imposed,
6
 feasibility of the science 
and technology,
7
 and precautionary principle.
8
  Opponents’ precaution 
is predicated on the principle that some technologies are so inherently 
dangerous to humankind; they should be considered a Pandora’s Box 
that should never be pursued, regardless of the potential benefits.
9
 
A. Thesis 
First, this paper will attempt to elucidate both sides of the 
controversial debate of enabling parents, by means of current Assisted 
Reproductive Technologies (ARTs) and future Reproductive Genetic 
Biotechnologies (RGBs), to choose the genes or genetic traits of their 
children.  The paper will examine current genetic engineering and 
future genetic modification technologies by evaluating their scientific 
feasibility, applicability, and development towards enabling parents to 
choose the genetics of their children.  Technologies such as: Gene 
Therapy, Germline engineering, and Human Artificial Chromosomes 
(HACs) will be discussed.  In addition, the advancement and impact 
of the Human Genome Project (HGP) will be examined in the context 
of its impact on the progression of past, present, and future genetic 
modification technologies.
10
 
Second, the social and bioethical implications of genetic 
modification will be examined in the context of the complex and 
diverse range of ideologies and perspectives from both prominent 
proponents and opponents of genetic modification.  Prolific 
proponents—such as Gregory Stock, Julian Savulescu, Lee Silver, 
and Ray Kurzweil—argue genetic engineering is a promising and 
desirable technology that could potentially revolutionize and 
transform humankind by improving our body and our minds.
11
  
Visceral opponents—such as Leon Kass, Francis Fukuyama, and Bill 
McKibben—argue inevitable genetic engineering technologies would 
radically redefine the definition of humankind by manipulating 
inheritable genetic and epigenetic traits such as: intelligence, athletic 
 
 6. See id. at xi. 
 7. See FRANCIS FUKUYAMA, OUR POSTHUMAN FUTURE: CONSEQUENCES OF THE 
BIOTECHNOLOGY REVOLUTION 82 (2002). 
 8. See Bill Joy, Why the Future Doesn’t Need Us, WIRED (Apr. 2000), 
http://www.wired.com/wired/archive/8.04/joy_pr.html. 
 9. See id. 
 10. STOCK, supra note 3, at 42. 
 11. See generally STOCK, supra note 3; RAY KURZWEIL, THE SINGULARITY IS NEAR: 
WHEN HUMANS TRANSCEND BIOLOGY (2005); JULIAN SAVULESCU ET AL., ENHANCING HUMAN 
CAPACITIES (2011); LEE M. SILVER, REMAKING EDEN (1998). 
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ability, and longevity.
12
  These opponents express deep concern of its 
potential destructive impact on the social, ethical, and philosophical 
framework of society.
13
 
Finally, the paper describes the current regulatory frameworks of 
governmental and nongovernmental agencies that exercise limited 
regulatory authority over genetic engineering technologies.  In 
addition, the paper examines the possible future regulations of genetic 
engineering technologies.  Lastly, the paper attempts to balance the 
costs and benefits of the relevant technologies against the social and 
bioethical implications in order to recommend guidelines for 
legislators to consider when seeking practical and prudent public 
policy solutions. 
I. UNDERSTANDING GENETIC ENGINEERING TECHNOLOGIES 
A. Assisted Reproductive Technologies (ARTs) 
ARTs include a wide range of medical treatments and 
procedures involving the manipulation of human eggs and sperm 
inside and outside the human body.
14
  ARTs such as, In Vitro 
Fertilization (IVF), and Pre-implantation Genetic Diagnosis (PGD) 
have been gateway technologies to all the advanced reproductive 
technologies now emerging, in addition to prospective technologies 
such as germline engineering.  Moreover, as humankind’s 
understanding of our genomic information and genes that correspond 
to disease linked genetic markers increase as a result of the Human 
Genome Project (HGP), the intersection of IVF, PGD, and genomics 
may potentially form the requisite catalyst needed to enable parents to 
choose the positive genetic traits and characteristics of their 
offspring.
15
 
 
 12. See generally PRESIDENT’S COUNCIL ON BIOETHICS (U.S.), BEYOND THERAPY: 
BIOTECHNOLOGY AND THE PURSUIT OF HAPPINESS (2003) [hereinafter BEYOND THERAPY]; 
FUKUYAMA, supra note 7; BILL MCKIBBEN, ENOUGH: STAYING HUMAN IN AN ENGINEERED 
AGE xi-xiii (2003). 
 13. Id. 
 14. See 42 U.S.C. § 263a-7(1) (2006) (“The term “assisted reproductive technology” 
means all treatments or procedures which include the handling of human oocytes or embryos, 
including in vitro fertilization, gamete intrafallopian transfer, zygote intrafallopian transfer, and 
such other specific technologies.”). 
 15. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 102; see also Susannah 
Baruch, Preimplantation Genetic Diagnosis and Parental Preferences: Beyond Deadly Disease, 
8 HOUS. J. HEALTH L. & POL’Y 245, 251 (2008). 
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B. The Human Genome Project (HGP) 
Until the HGP was proposed, scientists had to work with small 
portions of genetic material, usually consisting of only a few genes as 
they struggled to understand how genetic mutations caused diseases.
16
  
Although the HGP offers great promise for humankind to gain control 
of our evolution, this is far from the minds of scientists working 
toward understanding the genome.  Scientists are more focused on 
disease prevention: “identifying disease-related genes, developing 
diagnostic tests, finding effective new drugs, understanding cancer 
and other diseases.”17  The ambitious goals of the HGP included two 
revolutionary outcomes: (1) “the genome was mapped at a relatively 
high level. This means that researchers systematically determined the 
linear order of genes on each chromosome using applied genomics to 
identify and localize genes in a process known as transcript 
mapping,”18 and (2) “[t]he Messenger RNA transcripts from 
expressed genes are converted to complementary DNAs (cDNAs), 
which are then sequenced and mapped to sites on particular 
chromosomes.”19  This revolutionary work in genomic analysis and 
gene mapping was completed with the announcement in 2003 of the 
completion of sequencing the 3-billion-base pairs of Human DNA.
20
  
The project reinvigorated the aspirations of those seeking to improve 
the human race through genetic engineering and reproductive 
technologies.  With the completion of sequencing the human genome, 
researchers are more able to quickly and easily diagnose genetic 
diseases and identify life-threatening prenatal genetic abnormalities.
21
 
Since its completion in 2003, remarkable innovations in genetic 
mapping and computational power have increased the speed, 
accuracy, and efficiency of sequencing the human genome with recent 
techniques demonstrating rapid and non-invasive Whole-Genome 
Sequencing (WGS) of a human fetus for genetic diagnosis.
22
  Gregory 
 
 16. See John Robertson, Procreative Liberty in the Era of Genomics, 29 AM. J.L. & MED. 
439-40 (2003). 
 17. STOCK, supra note 3, at 42. 
 18. ROBERT P. MERGES ET AL., INTELLECTUAL PROPERTY IN THE NEW TECHNOLOGICAL 
AGE 568 (2010). 
 19. Id. 
 20. See U.S. Dep’t of Energy, About the Human Genome Project, HUMAN GENOME 
PROJECT INFORMATION ARCHIVE 1990–2003, 
http://web.ornl.gov/sci/techresources/Human_Genome/project/index.shtml. 
 21. See Maxwell J. Mehlman, The Law of Above Average: Leveling the New Genetic 
Enhancement Playing Field, 85 IOWA L. REV. 517, 521-22 (2000). 
 22. See Jacob O. Kitzman et al., Non-Invasive Whole Genome Sequencing of a Human 
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Stock, a proponent of genetic engineering technologies and futurist 
recognizes the HGP as an “extraordinary accomplishment, [where] 
humanity took a giant step toward unraveling its biology and 
manipulating it in profound ways.”23  Stock envisions that “[t]he 
immediate consequence of uncovering the more than thirty thousand 
human genes and their variants will be better identification of our 
genetic susceptibilities to various diseases and better treatments for 
them.”24  However, Stock also anticipates that with the completion of 
the HGP, and a better understanding of our gene related traits and 
characteristics, future RGBs will be developed to purposely 
manipulate our genes with somatic cell therapy.
25
  In contrast, others 
have expressed concerns about the completion of the HGP, and the 
consequences of the future use of genomic sequencing in 
reproduction, because it raises important social and ethical questions 
about people deciding to procreate based on their genetic makeup, or 
that of their embryo or fetuses.
26
 
1. Genome Sequencing 
Since the completion of the HGP, several companies have 
capitalized on the opportunity to provide consumers with a 
confidential, fast, and relatively inexpensive detailed analysis of their 
genetic information.  These services genotype an individual’s genetic 
information and compare it against the probabilities that other 
individuals who share the same specific genetic traits or genomic 
markers may have previously experienced medical complications.
27
  
 
Fetus, 4 SCI. TRANSLATIONAL MED. 1 (June 6, 2012); see also Ying-Ming Zheng et al., Whole 
Genome Amplification in Preimplantation Genetic Diagnosis, 12 J. ZHEJIANG U.-SCI. B 
(BIOMEDICINE & BIOTECHNOLOGY) 1 (2011); cf. Greer Donley et al., Prenatal Whole Genome 
Sequencing: Just Because We Can, Should We?, HASTINGS CENTER REP. July-Aug. 2012, 28, 42 
(raising important ethical concerns surrounding the application of pre-natal WGS for trait 
selection).  Next-Generation Screening (NGS) is poised to transform IVF and PGD by enabling 
whole genome sequencing of an embryo prior to implantation—thereby enabling parents to 
accept or reject an otherwise healthy embryo based on its pre-disposition of developing specific 
diseases later in life. 
 23. STOCK, supra note 3, at 41. 
 24. Id.; but cf. International Human Genome Sequencing Consortium, Finishing the 
Euchromatic Sequence of the Human Genome, 431 NATURE 931, 945 (2004) (stating that in the 
initial analysis of the draft sequence, scientists estimated approximately 30,000 human protein 
coding genes, which was later discovered to be in the range of 20,000-25,000). 
 25. See STOCK, supra note 3, at 42. 
 26. See Robertson, supra note 16, at 440-41. 
 27. See MIKE MACPHERSON ET AL., ESTIMATING GENOTYPE-SPECIﬁC INCIDENCE FOR 
ONE OR SEVERAL LOCI (2007), available at https://23andme.https.internapcdn.net/res/pdf/HIC-
SXIYiYqXreldAxO5yA_23-01_Estimating_Genotype_Specific_Incidence.pdf. 
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In addition, an individual’s “genotype-speciﬁc risk” is calculated 
based on the probabilities those other individuals who share similar 
genetic markers have the propensity to develop, or have developed, 
diseases such as diabetes expressed through different clinical research 
studies.
28
  These new genetic genotyping services essentially 
formulate their analysis based upon two layers of abstraction; 
probabilities on top of probabilities.  However inherently abstract 
these probabilities may seem at first glance, these testing services are 
continuously refining their formulations, which have been found to be 
surprisingly accurate for not sequencing an individual’s complete 
genome.  These direct-to-consumer genome-testing services only 
examine an individual’s exome, or the 1% of an individual’s genome 
variants and phenotypes most likely to contain information relating to 
specific markers for genetic traits or diseases.
29
  Although these 
services are still developing as a result of the completion of the HGP, 
the speed and price required to sequence an individual’s genome is 
falling rapidly, and in the foreseeable future complete genome 
sequencing, (not just the exome) may become as routine as a blood 
test in facilitating genetic modification.
30
 
2. Genomic Therapy and Enhancement 
As genomic sequencing becomes more ubiquitous, and public 
perception becomes more aware of genetic deficiencies or undesirable 
traits of an individual’s genome, public attitudes towards funding 
genetic modification research may change.  Proponents of genetic 
engineering argue the distinction between “therapy” and 
“enhancement” may one-day ultimately merge as a result of the 
HGP’s transformation of ubiquitous whole genome screening.31  As a 
result, public attitudes may shift the public debate of “therapy” 
towards support of genetic engineering technologies that could cure 
an individual’s potential disposition towards genetic mutations or 
epigenetic cancer causing abnormalities in their genome.  Proponents 
would likely agree such a shift in societal attitudes will come as more 
and more individuals have their genome analyzed, and learn that they 
may be more likely to develop genetic complications such as: 
coronary heart disease, atrial fibrillation, or even debilitating 
 
 28. See id. 
 29. See Adam Kiezun et al., Exome Sequencing and the Genetic Basis of Complex Traits, 
44 NATURE GENETICS 623 (2012). 
 30. See STOCK, supra note 3, at 46. 
 31. Cf. id. 
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conditions such as diabetes, Alzheimer’s or Parkinson’s disease.32  
Such a dramatic shift in genetic knowledge may shift public 
perception to redefine therapy to include “preventable therapies,” 
which would support RGBs. 
On the other hand, since the completion of the HGP, opponents 
of genetic research take a precautionary approach towards the 
discussion of the HGP’s role in genetic engineering because it may 
lead to enhancement that goes beyond correcting predisposition to 
disease.
33
  Proponents argue in support of going beyond therapy for 
enhancement, because if such improvement of human performance 
becomes feasible it could begin a “golden age” for humankind’s 
quality of life.
34
  It is no surprise then, that the sensationalized term 
“designer babies”35 has gained recent attention in the media in respect 
to this “golden age” of genomic research with coming prospects such 
as: “children born with improved genetic endowments, the result 
either of careful screening and selecting of embryos carrying 
desirable genes, or of directed genetic change (‘genetic engineering’) 
in gametes or embryos.”36  Opponents understand “directed genetic 
change” or genetic engineering to go beyond what random 
reproductive chance has provided, by improving embryos directly by 
introducing better genes.
37
  Futurists such as Stock, acknowledge that 
“[t]he media has hyped many recent gene discoveries, but there is no 
question that our genes do shape our predisposition and 
vulnerabilities.  The complexity of most of these influences remains 
to be determined, but a few are surprisingly simple.”38  However, 
proponents of genetic engineering contend that these futuristic claims 
of “designer babies” may not be as sensationalized as they may first 
appear.  Genetic engineering technologies such as gene transfer, 
germline engineering, and Human Artificial Chromosomes (HACs)—
in conjunction with current ARTs—have already shown success with 
 
 32. See Robertson, supra note 16, at 461; see also MARK S. FRANKEL & AUDREY R. 
CHAPMAN, HUMAN INHERITABLE GENETIC MODIFICATIONS (2000), available at 
http://srhrl.aaas.org/projects/human_enhance/reports/germline.pdf. 
 33. See BEYOND THERAPY, supra note 12, at 4. 
 34. NATIONAL SCIENCE FOUNDATION, CONVERGING TECHNOLOGIES FOR IMPROVING 
HUMAN PERFORMANCE 6 (2002). 
 35. See Bonnie Steinbock, Designer Babies: Choosing Our Children’s Genes, 372 THE 
LANCET 1294, 1294 (2008). 
 36. BEYOND THERAPY, supra note 12, at 29. 
 37. See id. at 31. 
 38. STOCK, supra note 3, at 43. 
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directed genetic change in non-human animal embryos in primates.
39
  
These experiments include revolutionary gene-editing techniques 
called Crispr and intracytoplasmic sperm injection (ICSI) to produce 
genetically modified non-human primates for research, which resulted 
in the birth of a healthy rhesus monkey male, named “George.”40 
C. Genetic Modification Technologies 
Genomic genotyping and the development of ARTs currently 
being used to treat genetic illnesses could eventually be applied to 
identify and enhance a person’s non-disease genetic characteristics or 
traits.  This broad term of genetic modification includes genetic 
engineering, which is “the genetic alteration of embryos before 
implantation in the womb, or, more radically, the genetic alteration of 
sperm or ova before conception.  In theory scientists could add genes 
that produce desirable traits (such as health, beauty, and intelligence) 
or subtract genes that produce undesirable traits (such as disease).”41  
There are several methods of trying to produce children naturally with 
superior genetic endowments, such as: “somatic enhancements in 
adults and children, pre-conception enhancement, selective abortion, 
embryo selection, and germline enhancement.”42  However, this paper 
will focus primarily on the direct manipulation of genes such as gene 
insertion or deletion.  These techniques, otherwise known as RGBs 
constitute a genetic intervention: “(1) when it is undertaken for the 
purpose of improving a characteristic or capability that, but for the 
enhancement, would lie within what is generally accepted as ‘normal’ 
range for humans; or (2) when it installs a characteristic or capability 
that is not normally present in humans.”43  These interventions are 
still futuristic in many respects and do not currently allow parents to 
screen or enhance characteristics such as height, eye color, 
intelligence, or a myriad of other traits; however, the technology is 
advancing rapidly and as one scientist and futurist observes the time 
 
 39. See BEYOND THERAPY, supra note 12, at 29. 
 40. See Anthony W.S. Chan et al., Foreign DNA Transmission by ICSI: Injection of 
Spermatozoa Bound with Exogenous DNA Results in Embryonic GFP Expression and Live 
Rhesus Monkey Births, 6 MOLECULAR HUM. REPROD., no. 1 26-33 (2000); Yuyu Niu et al., 
Generation of Gene-Modiﬁed Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in 
One-Cell Embryos, 156 CELL 836 (2014) (stating that researchers in China have created 
genetically modified monkeys using a new method of precise gene targeting known as Crispr, 
which can alter a DNA sequence at a specific location within a genome). 
 41. KERRY L. MACINTOSH, ILLEGAL BEINGS: HUMAN CLONES AND THE LAW 41 (2005). 
 42. Mehlman, supra note 21, at 524. 
 43. Id. at 523. 
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to address these challenges has arrived: 
The coming challenges of human genetic enhancement are not 
going to melt away; they will intensify decade by decade as we 
continue to unravel our biology, our nature, and the physical 
universe.  Humanity is moving out of its childhood and into a 
gawky, stumbling adolescence in which it must learn not only to 
acknowledge its immense new powers, but to figure out how to use 
them wisely.  The choices we face are daunting, but putting our 
heads in the sand is not the solution.
44
 
The social, ethical, and legal challenges of genetic enhancement 
require acknowledgement, but more importantly, recent 
advancements in biotechnologies such as germline engineering 
represent a paradigm shift—an early-stage embryo that can be 
genetically enhanced prior to IVF implantation will likely have 
profound implications that will redefine humanity.  Three such 
technologies will be discussed in the context of genetic engineering: 
(1) gene transfer or somatic gene therapy, (2) germline engineering or 
Inheritable Genetic Modification (IGM), and (3) Human Artificial 
Chromosomes (HACs). 
1. Somatic Gene Therapy 
Research and development in somatic gene therapy has 
responded to inheritable genetic diseases in existing adults that have 
been identified as a result of the completion of the HGP.  Currently, 
first generation gene therapy technology targets cells other than 
embryo or sperm cells and works by targeting common monogenic 
diseases such as Duchenne muscular dystrophy and cystic fibrosis.
45
  
The process involves transferring normal or healthy cells into the 
somatic cells or tissue of the patient, producing genetic changes that 
are restricted to the individual and not inheritable to future 
offspring.
46
  More specifically, the process “involves physical 
(microinjection), chemical (charged lipid carriers of DNA), and viral 
methods to introduce the normal gene in chosen target cells.”47  Once 
the injection has replaced the abnormal or missing gene, the gene is 
expressed by “viral ‘vectors’ containing the inserted therapeutic DNA 
 
 44. STOCK, supra note 3, at 17. 
 45. See S. M. Selkirk, Gene Therapy in Clinical Medicine, 80 POSTGRADUATE MED. J. 
560, 560-70 (2004); see also Donald B. Kohn & F. Candotti, Gene Therapy Fulfilling its 
Promise, 360 NEW ENG. J. MED. 518, 518-21 (2009). 
 46. See STOCK, supra note 3, at 38. 
 47. MERGES ET AL., supra note 18, at 612. 
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[which] are attenuated or modified versions of viruses that are 
incapable of replicating in the patient, but retain the ability to 
efficiently deliver DNA to the cell.  These ‘vectors’ also contain 
promoters that turn the normal gene on and off.”48  Past gene therapy 
clinical trials have achieved little success, primarily because the 
human body is made up of trillions of cells and for the gene therapy to 
be effective, millions of cells need to be altered.
49
  Furthermore, with 
the death of Jesse Gelsinger in 1999, while participating in a gene-
transfer clinical trial, greater regulatory oversight of gene therapy has 
been imposed by the U.S. Food and Drug Administration (FDA).
50
 
However, second generation gene therapy technologies may 
prove more successful, because they target the incorporation of genes 
into the cell nucleus using a Trojan horse approach, where “[i]nstead 
of using a cellular virus to transfect the cells, this approach would 
introduce gene sequences by ‘disguising’ them as a molecule 
recognized by the cell and passing them through the cell 
membrane.”51  Gene transfer techniques face two principal obstacles 
to their safe and effective use: “[F]irst, the exact locations in the host 
DNA into which new genetic information is inserted and, second, the 
extent to which the new genes are expressed in the right cells at the 
correct developmental time (without inducing other unwanted gene 
expression or altered regulation of resident genes).”52  These obstacles 
have led researchers to experiment with other methods of gene 
transfer, such as anti-genes and germline engineering that, unlike 
somatic cell therapy, only requires gene modification once to the 
reproductive cells of the embryo.
53
 
2. Germline Engineering or Inheritable Genetic 
Modification (IGM) 
Germline engineering or the term “germline” refers to the 
“germ” or “germinal” cells of the eggs and sperm that are targeted for 
genetic modification.
54
  Advances in biotechnology raise the 
possibility that ARTs such as PGD may move beyond simply 
 
 48. Id.; see REPRODUCTION AND RESPONSIBILITY, supra note 5, at 105. 
 49. See FUKUYAMA, supra note 7, at 76. 
 50. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 113. 
 51. MERGES ET AL., supra note 18, at 612. 
 52. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 107. 
 53. See LEE M. SILVER, REMAKING EDEN 273 (1998). 
 54. See ASS’N OF REPRODUCTIVE HEALTH PROFESSIONALS, HUMAN CLONING AND 
GENETIC MODIFICATION: THE BASIC SCIENCE YOU NEED TO KNOW, available at 
http://www.arhp.org/uploadDocs/cloning.pdf [hereinafter ARHP]. 
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diagnosing or selecting embryos for particular traits, to genetic 
modification or engineering embryos for desired characteristics by 
changing the genes in a progenitor’s gametes.55  Current germline 
engineering technology represents such a shift in human reproduction 
as it incorporates normal cells into the germline or reproductive cells, 
essentially becoming part of the permanent genome of the offspring, 
which unlike somatic gene therapy would be passed onto the next 
generation through reproduction.
56
  This multistep germline 
modification process includes: (1) using IVF to create a single-cell 
embryo or zygote that develops into the blastocyst stage; (2) 
embryonic stem cells are removed from the blastocyst, and the stem 
cell genes are modified using viral vectors; (3) modified stem cells 
colonies are tested for successful incorporation of the new genes; (4) 
a cloning process transfers the modified stem cell nucleus into an 
enucleated egg cell; and finally (5) the newly constructed embryo 
would then be implanted into a woman’s uterus and after gestation 
would produce a genetically modified child.
57
 
Although the science and technology required to enable parents 
to choose the genetic traits and characteristics of their children 
continues to remain speculative, researchers involved in recent 
genetic modification studies of mice and primates
58
 believe scientific 
breakthroughs are inevitably pushing us closer to germline 
modification in humans.
59
  Recent experimental breakthroughs 
demonstrating the technological feasibility of germline modification 
in mice have shown researchers can use sperm and eggs grown from 
Induced Pluripotent Stem Cells (iPSCs) for reproduction—a 
breakthrough theorized by some scientists involved in the project that 
could be applied not just to mice, but in other mammals as well, 
including humans.
60
  In a second recent scientific breakthrough in 
germline modification, a new generation of genetically modified mice 
were developed using Haploid Embryonic Stem Cells (haESCs); a 
technique that researchers speculated could be used in the future to 
correct genetic diseases in germ cells not just of mice, but of humans, 
 
 55. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 106. 
 56. See ARHP, supra note 54; see also MERGES ET AL., supra note 18, at 612. 
 57. See ARHP, supra note 54. 
 58. See Anthony W.S. Chan et al., Transgenic Monkeys Produced by Retroviral Gene 
Transform into Mature Oocytes, 291 SCIENCE 309, 309-12 (2001). 
 59. See Katsuhiko Hayashi et al., Offspring from Oocytes Derived from in Vitro 
Primordial Germ Cell–Like Cells in Mice, 338 SCIENCE 971, 971 (2012). 
 60. See id. 
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too.
61
  Finally, biologists have recently succeeded in cloning human 
stem cells by reprogramming somatic cells into pluripotent embryonic 
stem cells (ESCs) through somatic cell nuclear transfer (SCNT).
62
  
This groundbreaking technique produces human stem cells without 
the ethical implications that accompany the creation and destruction 
of human embryos—which could have significant implications for 
research of pluripotent stem cell regenerative medicines.
63
  These 
scientific breakthroughs illustrate proponents’ arguments that IGM is 
not only scientifically feasible, but could also be used to allow 
couples to avoid passing on serious genetic diseases, and have healthy 
offspring that is genetically related to both parents.
64
 
Proponents of IGM such as Stock, reiterate that “[g]ermline 
engineering represents a shift in human reproduction, but as effective 
somatic therapies become common, reduced public concern about 
genetic interventions in general will smooth the way for a move from 
screening and selecting embryos to actually manipulating them.”65  
However, critics of human germline manipulation “frequently point to 
the risks of passing on genetic errors to future generations.  But even 
if errors are entirely preventable, making our early genetic 
modifications permanent parts of the human genome pool would be 
foolish.”66  Opponents such as Fukuyama are in limited agreement 
with Stock’s perspective that germline engineering represents 
potentially the most consequential development in biotechnology.  
“The reason for this is that human nature is fundamental to our 
notions of justice, morality, and the good life, and all of these will 
undergo change if this technology becomes widespread.”67  Yet, both 
proponents and advisory agencies recognize the many shortcomings 
of germline engineering, and recommend that even if such genetic 
 
 61. See Hui Yang et al., Generation of Genetically Modified Mice by Oocyte Injection of 
Androgenetic Haploid Embryonic Stem Cells, 149 CELL 605, 605-17 (2012); see also Wei Li et 
al., Androgenetic Haploid Embryonic Stem Cells Produce Live Transgenic Mice, 490 NATURE 
407 (2012), available at http://dx.doi.org/10.1038/nature11435.  From Embryonic Stem Cells, a 
Sperm Replacement and Easier Path to Genetic Modification, PHYS.ORG (Apr. 26, 2012), 
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 62. See Masahito Tachibana, et al., Human Embryonic Stem Cells Derived by Somatic 
Cell Nuclear Transfer, 153 CELL 1228, 1228-38 (2013). 
 63. See Thomas A. Rando, Stem Cells, Ageing and the Quest for Immortality, 441 
NATURE 1080, 1080-86 (2006); Katharine Brown et al., SIRT3 Reverses Aging-Associated 
Degeneration, 3 CELL REP. 319, 319-27 (2013). 
 64. See STOCK, supra note 3, at 56; see also BEYOND THERAPY, supra note 12, at 5. 
 65. STOCK, supra note 3, at 39. 
 66. Id. at 69. 
 67. FUKUYAMA, supra note 7, at 82-83. 
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errors could be reversed, safer alternatives should be pursued that 
minimize potential germline risks.
68
 
3. Human Artificial Chromosomes (HACs) 
The discussion surrounding current somatic gene therapy and 
germline genetic engineering technologies looks to minimize the 
safety risks, complexity, and costs associated; while maximizing 
flexibility, general application, and future technological adaptation.  
Researchers looking beyond current genetic engineering 
developments believe an answer has emerged in the form of a 
technology called Human Artificial Chromosomes (HACs).  
Scientists predict HACs could be the archetypal futuristic answer to 
all the problems of expensive, complex, and risky gene transfer 
technologies.  However, HACs are not a relatively new technology, 
but rather were introduced in 1997, in a research article that first 
described the process of “combined long synthetic arrays of alpha 
satellite DNA with telomeric DNA and genomic DNA to generate 
artificial chromosomes in human HT1080 cells.”69 This fascinating 
introductory research claimed that, “[t]his first-generation system for 
the construction of human artificial chromosomes should be suitable 
for dissecting the sequence requirements of human centromeres, as 
well as developing constructs useful for therapeutic application.”70  
Research has developed slowly over the last decade, and focused 
primarily on gene delivery and transfer into stem cells.
71
  However, 
recent scientific advancements have stirred excitement with 
breakthroughs in gene therapy that have found HACs “exhibit several 
potential characteristics desired for an ideal gene delivery vector, 
including stable episomal maintenance and the capacity to carry large 
genomic loci with their regulatory elements, thus allowing the 
physiological regulation of the introduced gene in a manner similar to 
that of native chromosomes.”72  These breakthroughs with HAC 
research in animals highlight the technology’s potential maturity and 
future development, in contrast to several aforementioned genetic 
 
 68. See FRANKEL & CHAPMAN, supra note 32. 
 69. John J. Harrington et al., Formation of De Novo Centromeres and Construction of 
First-Generation Human Artificial Microchromosomes, 15 NATURE GENETICS 345, 345, 355 
(1997). 
 70. Id. 
 71. See Xianying Ren et al., Human Artificial Chromosome Vectors Meet Stem Cells, 2 
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 72. Y. Kazuki et al., Refined Human Artificial Chromosome Vectors for Gene Therapy 
and Animal Transgenesis, 18 GENE THERAPY 384, 384-93 (2011). 
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engineering technologies.
73
 
Proponents of genetic modification technologies propose 
widespread adoption will require generalized methods for germline 
modification and insertion, a problem in which the introduction of 
HACs could be the answer researchers have been searching for. The 
process would involve inserting a new chromosome pair (numbers 47 
and 48) into our genome that would act as framework or platform in 
which to add or remove genetic modules, instead of trying to modify 
the genes on one of our present 46 chromosomes.
74
  Compared to 
previous unreliable genetic modification techniques such as gene 
therapy, an artificial chromosome would provide a generalized and 
reproducible framework for adding and removing genetic material to 
cells, that could produce a reliable and potentially “safe” human 
germline technology.  Proponents argue that such a technology would 
revolutionize the conception of reproduction, and create a 
marketplace where: 
Parents will want the most up-to-date genetic modifications 
available.  Were these prospective parents’ own modifications 
scattered through their chromosomes, cleaning them out and 
upgrading them would be tricky, but with changes confined to an 
auxiliary chromosome, a parent could simply discard the entire 
thing and give his or her child a new version.
75
 
An advantage of such a technique could provide for “gene-packs” that 
could allow for hundreds, if not thousands of unique gene 
modifications to an embryo.
76
  Based on proponents’ futuristic 
predictions, HACs could solve many of the problems plagued by 
current genetic engineering technologies, and provide parents the 
option of passing on their chromosomal genetic upgrades to their 
children or discarding them.
77
  Futurists predict this technological 
advancement if successful, would result in a profound transformation 
of the human condition, because ultimately “it is a convergence of the 
processes that will bring us as well as machines into being and shape 
our natures.  Human conception is shifting from chance to conscious 
design.”78 
 
73
 See Yuwna Yakura et al., An induced pluripotent stem cell-mediated and integration-free 
factor VIII expression system, 431 BIOCHEMICAL AND BIOPHYSICAL RESEARCH 
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 74. See STOCK, supra note 3, at 66. 
 75. Id. at 69-70. 
 76. See SILVER, supra note 53, at 271. 
 77. See STOCK, supra note 3, at 70. 
 78. Id. at 75. 
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However, opponents of genetic modification such as Leon Kass, 
Chair of the President’s Council on Bioethics, concede that such 
futuristic artificial chromosomal genetic modifications such as HACs, 
would be a safer alternative to the known risks of gene therapy or 
inheritable alternatives such as IGM.
79
  Kass concedes that HACs 
(assuming a hypothetical agreement on their perceived safety), would 
have greater benefits over current genetic engineering technologies, 
because the creation and injection of artificial chromosomes would 
essentially enable “the new ‘better’ genes [to] be packaged in small, 
manufactured chromosomal elements that, on introduction into cells, 
would not integrate into any of the normal forty-six human 
chromosomes.  Such artificial chromosomes could, in theory, be 
introduced into ova or zygotes without fear of causing new 
mutations.”80  In realizing the potential benefits of HACs, Kass is 
careful to recognize the technology is far from practical, and there 
exist significant challenges to overcome, such as the fact that genes 
introduced on an artificial chromosome “would now be present in 
three copies (one from mother, one from father, and one on the extra 
chromosome) instead of the usual two, throwing off the normal 
balance of gene copies among all the genes.  The consequences of 
such ‘triploidy’ [could] be deleterious . . . .”81  Therefore, Kass’s 
superficial support of HACs over alternative genetic engineering 
technologies may simply be in response to the current unavailability 
of the technology, and belief that the safety risks will always pose a 
barrier to its adoption.  However, as research and development of 
HACs continues, only time will tell if the technology materializes into 
the futuristic visions proposed by proponents of genetic engineering, 
or as suggested by opponents, into another unrealized speculative 
technology with promise, but with far too many practical hurdles to 
overcome to become a reality.
82
 
 
 79. BEYOND THERAPY, supra note 12, at 37. 
 80. Id. 
 81. Id. Proponents would likely argue any reproductive safety concerns from opponents 
in respect to the feasibility of RGBs such as HACs, could simply be solved by removing or 
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 82. See FUKUYAMA, supra note 7, at 77; cf. Def. Advanced Research Projects Agency 
(DARPA), ST13B-001: Advanced Tools for Mammalian Genome Engineering, SBIR/STTR 
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least 50,000 base pairs (bp) in length into defined genomic loci, and new methodologies for 
facile intercellular genome transplantation”). 
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II. THE SOCIAL AND BIOETHICAL IMPLICATIONS 
There are numerous social and ethical concerns proposed by 
both proponents and opponents of Reproductive Genetic 
Biotechnologies (RGBs) that form the extensive and varied 
controversial public debate surrounding reproductive technologies.  
The public debate put forward by both proponents and opponents of 
genetic modification span a broad range of contentious issues that are 
beyond the scope of this paper which include: constitutional 
reproductive issues, gender selection, eugenics, cloning, and abortion.  
Therefore, the following discussion will be divided into two sections.  
First, proponents’ principle arguments in support of genetic 
engineering will be briefly introduced.  Second, opponents’ 
arguments against genetic engineering will be discussed, followed by 
corresponding rebuttals from proponents. 
A. Proponents of Genetic Engineering 
Proponents of RGBs have advanced numerous social, ethical, 
legal, and philosophical justifications.  Yet, many of these arguments 
advocating support of genetic engineering are articulated in rebuttals 
to opponents’ arguments against RGBs—discussed later in the paper 
in response to opponents’ various arguments.  However, for the 
purposes of lucidity, the following discussion will focus narrowly on 
only four of proponents’ most salient points: evolution, inevitability, 
defining life, and feasibility. 
First, proponents argue that humans have always acted in ways 
that affect the evolution of our species.  “Human action has shaped 
human biology and altered the genome as long as there have been 
human beings: a series of non-biomedical enhancements of human 
capacities, from the agrarian revolution . . . has trigged processes of 
natural selection and mixed previously isolated gene pools.”83  From 
this perspective, RGBs are just the next step along a path long since 
taken.  Moreover, a case can be made that humankind’s modern day 
socio-technological progress has exceeded its outdated biology, 
rendering it necessary to accelerate our biological evolution.  Gregory 
Stock articulates this point stating, “It is rather poignant that we 
cannot yet apply technology more directly to our biological selves, 
because the advances in transportation, telecommunications, and 
other areas that enable us to transcend some of our bodily limits give 
 
 83. ALLEN E. BUCHANAN, BEYOND HUMANITY?: THE ETHICS OF BIOMEDICAL 
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us the idea that we should also be able to stay our eventual aging and 
decay.”84 
Second, prominent proponents such as Julian Savulescu, argue in 
addition to Stock that “[g]enetic selection to determine how our 
children look, think and act isn’t recklessly playing God . . . . It’s a 
gift to future generations.”85  Savulescu articulates this modernist 
ideology of inevitability, an argument often posited by proponents, 
that “[i]f we have the power to intervene in the nature of our 
offspring—rather than consigning them to the natural lottery—then 
we should.  Surely trying to ensure that your children have the best, or 
a good enough, opportunity for a great life is responsible 
parenting?”86  This argument is founded on the conceptualization that 
if humankind has the ability to better our children, such 
improvements will be an inevitable consequence of providing for our 
offspring.  Whether the improvement occurs pre-gestation or post 
gestation is irrelevant, because society is still trying to care for their 
children.  This distinction of improvement analyzed from proponents’ 
perspective, lends credibility to the inevitability argument that, 
“[w]hether we like it or not, the future of humanity is in our hands 
now.  Rather than fearing genetics, we should embrace it.  We can do 
better than chance.”87 
Third, futurist proponents such as Lee Silver argue opponents 
maintain a controversial defect in their definition in human life, and 
that there is a serious flaw in the logical progression that leads people 
to adopt the idea that the “essence” of human life is contained within 
our genetic material.
88
  According to Silver, the flaw is caused by the 
inability of opponents to separate the different meanings of the word 
“life” at the level of the individual embryo and at the level of human 
consciousness.
89
  This extremely important, yet controversial and 
complex discussion of attempting to define exactly when life begins, 
from either a theological or scientific perspective, is far beyond the 
scope of this paper.  However, this important principle remains a 
fundamental differentiation between proponents and opponents, and 
provides further context to understanding justifications for or against 
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RGBs.  Silver and other proponents recognize the difficulty and 
futility of influencing opponents’ definition of human life.  As a 
result, proponents typically avoid advancing such arguments in favor 
of focusing on the benefits RGBs can bring to existing human life and 
the feasibility of the technology for prevention of genetic disease. 
Fourth, proponents reject assertions that genetic modification is 
still highly speculative and thus not deserving of rational discourse.  
The crucial enabling technology for germline engineering was 
discovered in 1980,
90
 and since then has seen advancements in 
“knocking out” or silencing genes.91  These advancements were 
discovered in 2001, which include a new classification of ribo-nucleic 
acids (RNAs) that selectively silence genes after transcription.
92
  
Researchers introduce a specific germline modification in a mouse 
gene by injecting the mouse’s fertilized eggs with DNA and grow 
embryonic stem cells encoding the intended change.
93
  Researchers 
then inject the selected embryonic stem cells into a blastocyst, which 
is implanted in the foster mother mouse.
94
  After gestation, the mother 
gives birth to chimeric mice that when mated with normal mice can 
give birth to mice with the targeted gene, thereby producing a “knock-
out strain” in the subsequent mouse generation.95  Some proponents 
have considered this development of knocking-out genes in the next 
generation of mice as a cornerstone of germline engineering research 
that will one day enable parents to select and manipulate the genetics 
of their children.
96
  Moreover, proponents often synthesize these four 
main arguments when predicting future research and development in 
genetic engineering will inevitably lead to human genetic 
manipulation.  Therefore, it’s argued that “inevitability” of RGBs 
defeat opponents’ arguments of feasibility, because such 
advancements are the logical conclusion of our ongoing evolution in 
reproductive biology.
97
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1. Procreative Liberty and Genetic Engineering 
Some proponents of RGBs argue that parents should be free to 
choose the genetic disposition of their children.  John Robertson, who 
takes a moderate perspective on genetic engineering,
98
 classifies 
procreative liberty proponents of RGBs as either radical libertarians 
or modern traditionalists.
99
  Modern traditionalists hold “reproductive 
choice in a liberal, rights-based society is a basic freedom, including 
the use of genetic and reproductive technologies that are helpful in 
having healthy, biologically related offspring.”100  Radical libertarians 
would arguably support any form of genetic modification regardless 
of its purpose,
101
 based on the fundamental principles of individual 
liberty, autonomy, and freedom, whereas modern traditionalists’ 
“acceptance of reproductive and genetic technologies . . . exists only 
insofar as they aid the task of successful reproduction, and do not 
directly harm offspring, families, women, society, or others.”102  This 
perspective balances the benefits of non-medical genetic selection 
against the perceived costs and safety risks involved in such a 
selection.  Therefore, justification for positive genetic modification of 
our children’s genes, from a modern traditionalist perspective, would 
depend on the parent’s reasons and whether it occurs as a result of 
therapeutic alteration or non-therapeutic alteration.
103
 
a. Therapeutic Alteration 
First, arguments advanced in support of IGM for therapeutic 
purposes focus on allowing couples to avoid passing on serious 
genetic diseases, such as “sickle cell anemia, Tay Saches disease, or 
cystic fibrosis.”104  However, opponents in rebuttal, claim other less 
risky methods already exist to accomplish the same goal, such as 
PGD that requires no manipulation of the germline.
105
   Secondly, 
proponents posit that IGM can allow couples that both share a 
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defective gene to have a healthy child that is related to both of them, 
rather than produce no child at all.
106
  Yet, opponents still reject such 
assertions, because such cases are likely to be a very rare and small 
percentage to warrant IGM.
107
  Lastly, proponents conclude that 
human IGM clinical trials need to continue in order to establish that 
the science and process behind therapeutic modification becomes safe 
and effective.
108
  Therefore, any inherent risk or harm to the child, if 
minimized, would be a generally acceptable risk of medical 
progress.
109
 
b. Non-therapeutic Alteration or Enhancement 
First, proponents argue that if IGM could allow couples to 
“enhance” their children to be healthier, more athletic, intelligent, or 
attractive, such enhancement is supported by procreative liberty 
whether it occurs pre-birth or post-birth.
110
  However, opponents 
refute such claims, because non-therapeutic enhancement would 
likely be permanent and affect future generations, and because genetic 
modifications are very different in quality and kind than post-birth 
enhancements.
111
 
Second, proponents recognize the inherent threat to equality if 
genetic enhancement becomes so essential for reproduction it would 
require parents to engage in a genetic arms race for their children.
112
 
Many think that it is inherently unfair for some people to have 
access to technologies that can provide advantages while others, 
less well-off, are forced to depend on chance alone.  I would agree.  
It is inherently unfair.  But American society adheres to the 
principle that personal liberty and personal fortune are the primary 
determinants of what individuals are allowed and able to do.  
Anyone who accepts the right of affluent parents to provide their 
children with an expensive private school education cannot use 
‘unfairness’ as a reason for rejecting the use of reprogenetic 
technologies.
113
 
Therefore, proponents and opponents would likely agree that 
there exist serious risks of genetic social stratification, but it is unclear 
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at what point proponents agree such risks warrant government 
regulation.  In order to understand these complex issues and frame 
solutions to these future genetic societal problems, risks must also be 
examined in the context of post-humanism. 
2. Our Post-Humanism Future 
Many proponents of genetic engineering suggest if humankind 
were to adopt genetic engineering technologies that enable parents to 
choose the genetic characteristics of their children, and were to take 
the science a step further—to choose desirable genetic enhancements 
and abilities, such as sharper eyesight, better hearing, stronger 
immune systems, or greater intelligence—would the child still be 
considered human?
114
  When framing humankind’s existence and 
identity in this continually evolving context, one must accept that due 
to constantly changing somatic and germ-line mutations, the genetic 
composition of who we are today, is not who we were yesterday.  
This reconceptualization of existence is necessary to understand the 
post-humanist movement’s principles as humankind looks to new 
frameworks to define life.  Ray Kurzweil attempts to answer the 
question of identity in that, “I am rather like the pattern that water 
makes in a stream as it rushes past the rocks in its path.  The actual 
molecules of water change every millisecond, but the pattern persists 
for hours or even years.”115  This poignant example forces us to re-
examine the importance of our ideological belief that we define our 
existence not by the atoms or particles that make our bodies, but 
rather the pattern of our life form that existentially creates the essence 
of our being.  In that sense, if we were to alter our physical bodies 
with futuristic RGBs such as those proposed, after such radical 
genetic modifications, would we continue to exist or simply be 
replaced by somebody or something else?  “At bare minimum, even if 
enhancement brings such goodies as superhuman intelligence and 
radical life extension, it must not involve the elimination of any of 
your essential properties.  For in that case . . . they would not be 
experienced by you—they would be experienced by someone else.”116  
This quintessential point illustrates that this reconceptualization of 
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human existence as a result of the ultimate genetic enhancements, 
could lead to enhancing our children beyond their essential properties, 
which would be tantamount to suicide.  It is precisely these types of 
complex philosophical issues surrounding autonomy and existence 
that require the social and ethical implications of this post-humanism 
movement to be considered as equally important as the progression of 
the technologies themselves.  If humankind ever chooses to adopt the 
benefits of this transformation, how it chooses to define the human 
condition and its impact on society will ultimately determine if RGBs 
are considered good or bad.
117
  The salience of this post-humanism, 
and evolutionary genetic prospective has also been articulated from 
philosophers such as Friedrich Nietzsche: 
All beings so far have created something beyond themselves; and 
do you want to be the ebb of this great flood and even go back to 
the beasts rather than overcome man?  What is the ape to man?  A 
laughingstock or a painful embarrassment.  And man shall be just 
that for the overman: a laughingstock or a painful embarrassment.  
You have made your way from worm to man, and much in you is 
still worm.  Once you were apes, and even now, too, man is more 
ape than any ape.
118
 
Whether man is in fact still an ape in the context of our current 
evolutionary perspective, or has already achieved natural evolutionary 
perfection is one of the fundamental dichotomies between proponents 
and opponents of RGBs.  This divergence of ideologies is further 
explored by the following arguments advanced by opponents through 
their justifications of rejecting genetic modification technologies. 
B. Opponents of Genetic Engineering 
First, opponents of RGBs argue that public perception based on 
the pre-existing safe and successful biotechnological results of ARTs 
such as PGD, “may already be shifting parental and societal attitudes 
toward prospective children: from simple acceptance to judgment and 
control, from seeing a child as an unconditionally welcome gift to 
seeing him as a conditionally acceptable product.”119  However, such 
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“child product” arguments against PGD hold little weight in public 
perception.  The technology has already proven the procedure safe 
and effective; more than 1,000 babies have born worldwide
120
 without 
any noticeable impact on social attitudes toward children.  
Opponents’ perceptions may be accurate that public attitudes in 
support of PGD are shifting away from prevention of genetic 
diseases, to the selection of desired traits as the number of PGD 
procedures performed is increasing.
121
  However, proponents respond 
that regardless of whether PGD is becoming a normative technology 
in society, and whether that transformation is perceived as a positive 
or negative, both parties agree that the earlier screening occurs, the 
more likely it is that prospective parents will have healthy 
offspring.
122
 
Second, John Robertson characterizes many opponents of RGBs 
as strict traditionalists.
123
  A strict traditionalist “holds that 
reproduction is a gift from God, resulting from the loving intimacy of 
two persons.  They receive the gift of an embryo, fetus, and then child 
who is to be unconditionally cherished for its own sake.”124  A leading 
contemporary of strict traditionalism is Leon Kass, who postulates, 
“[w]hat’s at issue is not the crude old power to kill the creature made 
in God’s image but the attractive science-based power to remake 
ourselves after images of our own devising.”125  Kass uniquely 
articulates the social, ethical, and philosophical implications 
surrounding the debate of genetic modification from a strict 
traditionalist perspective and argues strenuously against genetic 
enhancement primarily because of its enormous potential to interfere 
with and diminish the purity of human nature.
126
  As he explains: 
In a word, one major trouble with biotechnical (especially mental) 
‘improvers’ is that they produce challenges in us by disrupting the 
normal character of human being-at-work-in-the-world, what 
Aristotle called energeia psyches, activity of soul, which when fine 
and full constitutes human flourishing.  With biotechnical 
interventions that skip the realm of intelligible meaning, we cannot 
really own the transformations nor experience them as genuinely 
ours.  And we will be at a loss to attest whether the resulting 
 
 120. See JUDITH F. DAAR, REPRODUCTIVE TECHNOLOGIES AND THE LAW 305 (2006). 
 121. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 90. 
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 123. See id. 
 124. Id. at 442. 
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conditions and activities of our bodies and our minds are, in the 
fullest sense, our own as human.
127
 
In this passage, Kass characterizes genetic enhancement 
biotechnologies as transformations that are not our own and, 
therefore, not human.  Thus, Kass frames the quintessential question, 
“‘What is biotechnology for?’ but also, ‘What should it be for?’”128  
The term biotechnology is understood to be “bigger than its processes 
and products; it is a form of human empowerment.  By means of its 
techniques (for example, DNA sequences), biotechnology empowers 
us human beings to assume greater control over our lives, diminishing 
our subjection to disease and misfortune, chance and necessity.”129  It 
is precisely this enthusiasm for biotechnology that attempts to answer 
the question what biotechnology is for, with the knowledge that the 
“discoveries of biologists and the inventions of biotechnologists are 
steadily increasing our power ever more precisely to intervene into 
the workings of our bodies and minds and to alter them by rational 
design.”130  The public debate surrounding these emerging 
technologies, from the perspective of strict traditionalists, has already 
provided unwanted answers to these rhetorical questions expressed 
simply by the “[v]ast numbers of people and their families [who] 
ardently await cures for many devastating diseases and eagerly 
anticipate relief from much human misery.  We will surely welcome . 
. . new technological measures that can bring us healthier bodies, 
decreased pain and suffering, peace of mind, and longer life.”131 
1. Going Beyond “Therapy” for “Enhancement” 
In contrast to proponents’ enthusiasm of biotechnology, 
opponents express caution in adopting these new biotechnologies that 
promise to usher in an era of healthier bodies, simply because “the 
prospect of genetic engineering, though welcomed for treatment of 
inherited genetic diseases, raises for some people fears of eugenics or 
worries about ‘designer babies.’”132  These fears form the crux of the 
strict traditionalist perspective and Kass’s argument—a perspective 
which is predicated on the concern of the emerging juxtaposition of 
 
 127. Leon R. Kass, Ageless Bodies, Happy Souls: Biotechnology and the Pursuit of 
Perfection, 1 NEW ATLANTIS 9, 24 (2003). 
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biotechnology applications in traditional medicinal use for healing, 
and those that go “beyond therapy,” thus improving the human 
condition for enhancement purposes.  Kass suggests that these broad 
concerns, “attach especially to these uses of biotechnology that go 
‘beyond therapy,’ beyond the usual domain of medicine and the goals 
of healing, uses that range from the advantageous to the frivolous to 
the pernicious.”133  Kass’s concerns justifiably find support in the 
public debate, primarily because his ideologies resonate with 
society’s cultural and historical understanding that enhancement for 
enhancement sake, goes beyond the purpose of healing and raises 
important theological concerns that “[n]ot everyone likes the idea of 
‘remaking Eden’ or of ‘man playing God.’”134 
Kass bemoans the tendency to dismiss these issues.  In his 
words, “questions raised by efforts to ‘improve on human nature’ 
seem abstract, remote, and overly philosophical, unfit for public 
policy; indeed, many bioethicists and intellectuals believe either that 
there is no such thing as ‘human nature’ or that altering it is not 
ethically problematic.”135  However, Kass notes that the distinction 
between therapy and enhancement is not too remote or abstract—
technologies that alter “human nature,” such as cosmetic surgery and 
performance enhancing drugs, are already pervasive in our society.
136
  
Public attention is warranted now, before a wave of new and more 
extreme technologies alter human nature and human society.
137
 
a. Seeking Perfection 
For these reasons strict traditionalists narrowly focus on the 
implications of the “well-meaning and strictly voluntary uses of 
biomedical technology through which the user is seeking some 
improvement or augmentation of his or her own capacities, or, from 
similar benevolent motives, of those of his or her children.”138  The 
different motivations behind therapeutic alterations and non-
therapeutic enhancements form an important cornerstone of 
opponents’ arguments, because in effect they form the guideposts 
between moral justification and condemnation.
139
  Strict 
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constructionists perceive “[s]uch use of biotechnical powers to pursue 
‘improvements’ or ‘perfections,’ whether of body, mind, 
performance, or sense of well-being, is at once both the most 
seductive and the most disquieting temptation.”140 
Differentiating between these two ideologies of therapy and 
enhancement arguably distinguish opponents’ Kantian philosophy, 
where the ends do not justify the means.  This moral perspective on 
self-augmenting capabilities, or the idea of enhancement, is 
understood as seeking something “better than normal” or human 
perfection itself.
141
  This reflection illustrates the “perfectionist” strict 
constructionist argument against RGBs, because such perfection or 
enhancement can only be seen as a means to an end.  Thus, those in 
pursuit of perfection must distort the modern day intended purpose of 
ARTs and RGBs, which is the prevention and curing of disease, in 
order to alleviate suffering.
142
 
b. Seeking Normality 
Kass rejects proponents’ arguments that support RGBs based on 
genetic inequality in order to pursue human normality.
143
  This 
controversial idea of normality is defined by the libertarian argument 
that the human condition and its capacities acquired at birth are no 
more than a product of pure chance.  As a result “[m]ost human 
capacities fall along a continuum, or a ‘normal distribution’ curve, 
and individuals who find themselves near the lower end of the normal 
distribution may be considered disadvantaged and therefore unhealthy 
in comparison with others.”144 
Predictably, Kass simultaneously acknowledges and dismisses 
the normality argument advanced by proponents of enhancement, 
because even though normality may not be driven by “perfection,” 
those who unluckily fall on the low-end of the culturally-relative 
spectrum, exist as a result of human nature; therefore, “[a]lthough less 
radical than the quest for ‘perfection,’ the quests for happiness, 
success, and self-esteem, especially in our society, may prove to be 
more powerful motives for an interest in using biotechnical power for 
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purposes that lie ‘beyond therapy.’”145  Kass concedes that, given the 
opportunity, “many of us might welcome biotechnical assistance in 
improving our native powers of mind and body, many more people 
will probably turn to it in search of advancement, contentment, and 
self-satisfaction—for themselves and for their children.”146  Yet, 
opponents are careful to differentiate that even though many people 
would pursue enhancement if available and proven safe, further study 
is still needed to determine the far-reaching implications, and whether 
accessibility to these biotechnologies will be equitably distributed.  If 
such genetic enhancements are pursued without regard for its social 
implications, opponents argue disastrous social consequences could 
follow.
147
 
c. Natural Limits Theory 
Kass characteristically poses the quintessential question of 
genetically engineering our children’s genes: “[w]hat parents would 
not wish to enhance the life of their children, to make them better 
people, to help them live better lives?”148  Parents fundamentally 
strive to improve and better their children by means of clothing, 
nutrition, education, and support until they become adults.  It has been 
this inherent concept of naturally improving our children that is under 
scrutiny, argues opponents, because present and projected 
biotechnologies will provide new and powerful means for improving 
our children.
149
  The moral and philosophical questions raised in 
response by Kass presuppose the improvement of our children, and 
the means best suited to accomplish these goals are inherently limited 
as a design of human nature.  Yet opponents recognizes these 
limitations are in actuality, inequalities placed on human nature itself: 
[N]ature sets limits on what can be accomplished by education and 
training alone.  No matter how much we try to help, the tone-deaf 
will need more training to learn to carry a tune, the short will be 
less likely to excel at basketball, the irascible will have trouble 
restraining their tempers, and the insufficiently smart will remain 
handicapped for competitive college admissions.
150
 
If our children’s natural “equipment” is faulty or limited by 
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means which will prevent them from realizing their true human 
potential (either by subjective or objective determinism), parents will 
naturally wish and seek out methods to improve or better their 
children as they have always done.  Improving our children in this 
context is a socially conditioned maxim that requires no justification, 
when “[e]ven before the coming of the present age of biotechnology, 
we have used technological adjuncts to improve upon nature’s gifts.  
We give our children supplementary vitamins, fluoridated toothpaste, 
and, where necessary, corrective lenses or hearing aids.”151  These 
culturally normative improvements and adaptations of our children’s 
gifts provide little support to Kass’s “natural limits” theory, which is 
further exacerbated by continued technological developments 
enabling parents to “use biological means of improving their 
[children’s] limited human capacity to resist disease: we immunize 
our children against polio, diphtheria, and measles, among other 
infectious diseases, by injecting them with attenuated viruses and 
bacteria in the form of vaccines.”152 
2. Safety Risks of Genetic Engineering 
Finally, opponents question the post-human agenda on biological 
and safety grounds.  In order for genetic engineering to be done, “one 
would first need to identify all (or enough) of the specific variants of 
genes whose presence (or absence) correlates with certain desired 
traits: higher intelligence, better memory, perfect pitch, calmer 
temperament, sunnier disposition, greater ambitiousness, etc.”153  
These socially normative “desired traits” of parents for their unborn 
children, even if they were discovered, are genetic traits heavily 
influenced by the external environment, which “are most certainly 
polygenic, that is, traits (or phenotypes) that depend on specific genes 
or their variants at several, perhaps many, distinct loci.”154  The 
complexity of these polygenic and epigenetic gene interactions would 
essentially prevent parents from choosing desired traits beyond simple 
single gene interactions such as height, eye, or hair color.
155
  
Furthermore, because many of the genes involved in the expression of 
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normal traits are “pleiotropic—that is, they influence many traits, not 
just one—even a properly inserted gene introduced to enhance a 
particular trait would often have multiple effects, not all of them for 
the better.”156  For these reasons, opponents conclude that any attempt 
to genetically modify or enhance normal “healthy” gametes or 
embryos would be unsafe, infeasible, and ethically suspect.
157
 
In response, proponents recognize that there exist numerous 
polygenic and epigenetic safety concerns that need to be addressed.  
However, if the technology is proven to be successful, it would only 
be introduced if it were possible to block genetic transmission to the 
next generation.
158
  Moreover, proponents understand that proving the 
technology to be successful will require inherently risky and 
unpredictable human clinical experimentation.  Yet, proponents are 
careful to argue that all medical progress does entail some risk within 
generally accepted parameters, and genetic modification could be 
reversed if problems occur.
159
  Furthermore, proponents argue that 
when viewing RGBs as a form of medical progress, any arguments 
against the use of medical assistance in reproduction would only be 
justified if based on a theological or metaphysical perspective of 
“natural” reproduction; essentially condemning all forms of 
technological assistance.
160
  Unless opponents believe that any 
interference with the natural process of reproduction is wrong, such 
an argument against medical progress could not withstand scrutiny, 
because societal technological advancements currently assist humans 
with the limitations nature has placed on them.  Proponents use this 
perspective to justify their argument that utilizing ARTs and, 
potentially, RGBs pre-birth to assist in the creation of life is no more 
objectionable than using technologies post-birth to sustain or support 
that life.
161
 
In contrast to proponents who are excited that RGBs will usher 
in a new era of human evolution, opponents such as Bill McKibben 
argue that it is wrong to alter human nature.
162
  According to 
McKibben, “What makes us unique is that we can restrain ourselves.  
We can decide not to do something that we are able to do.  We can set 
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limits on our desires.  We can say ‘Enough.’”163  McKibben argues 
we need to preserve humankind’s uniqueness before we lose our 
capacity for restraint.  As the availability of genetic enhancement 
technologies becomes as ubiquitous in society as elective cosmetic 
surgeries, or pharmaceutical enhancing drugs, the ability for 
humankind to define and retain its “essential properties” will become 
increasingly difficult.
164
  According to McKibben, we must question 
not only our desire to improve, but also how we choose to reach that 
goal.
165
 
3. Inequality Concerns of Genetic Discrimination 
If the proliferation of RGBs is only available to a select few who 
can afford them, the consequences will likely divide society and 
create two related problems: social inequality and unfairness.
166
  The 
division will likely further perpetuate social inequality and further 
entrench socio-economic stratification, because RGBs will initially 
only be available to those who can afford the elective procedures 
involved.
167
  IVF alone can cost an average of $37,000 per delivery; 
the genetic manipulations of embryos required will add further 
expense.
168
  Moreover, most health insurance does not cover IVF
169
 
and is unlikely to cover add-ons such as the engineering of 
embryos.
170
  Therefore, most people will not be able to afford RGBs.  
Society could attempt to minimize the threat to equality by providing 
universal coverage of genetic enhancements, or subsidizing their 
availability to the genetically disadvantaged.  Yet, such “utopian 
eugenics”171 would be prohibitively expensive, because such 
widespread access to enhancements that depended on IVF or PGD 
would cost $120 billion per year for IVF services alone.
172
  
Additionally, attempting to subsidize genetic enhancements would 
require identifying genetically disadvantaged individuals and groups, 
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which raise serous practical, moral, and political concerns.
173
  
Furthermore, because society will not be able to provide everyone 
with access to the same genetic enhancements the wealthy can 
purchase, there would continue to be an inherent inequality.
174
 
Employers and educators are an example of a constituency that 
will likely face new challenges in determining fairness and 
equitability in regulating standards for enhanced versus unenhanced 
individuals.
175
   For example, studies show that people who are tall 
and physically attractive are more likely to be hired and promoted 
than people who are short or unattractive.
176
  Genetically enhanced 
individuals could have an unfair advantage in competition for scarce 
societal and economic resources such as aptitude-based employment, 
or academic acceptance, because genetic enhancement could improve 
characteristics that are arguably suited for success and well-being.
177
  
Some commenters have even proposed futuristic scenarios in which 
unequal access to RGBs “eventually create[s] a political system 
dominated by a genetic aristocracy, or ‘genobility,’ that possesses a 
lock on wealth, privilege, and power.”178  As Francis Fukuyama 
states: 
What the emergence of a genetic overclass will do to the idea of 
universal human dignity is something worth pondering. . . . [T]o 
the extent that [bright and successful young people] become 
“children of choice” who have been genetically selected by their 
parents for certain characteristics, they may come to believe 
increasingly that their success is a matter not just of luck but of 
good choices and planning on the part of their parents, and hence 
something deserved.  They will look, think, act, and perhaps even 
feel differently from those who were not similarly chosen, and may 
come in time to think of themselves to be aristocrats, and unlike 
aristocrats of old, their claim to better birth will be rooted in nature 
and not convention.
179
 
However speculative these concerns of inequality may be, they 
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must be considered in the context of the future development of RGBs, 
and the public policies and regulatory oversight ensuring their safe 
and equitable adoption; otherwise opponents’ predictions of genetic 
engineering causing irreparable societal dysfunction may become a 
reality. 
 
III. POLICY RECOMMENDATIONS 
The public policy debate over germline engineering technologies 
and HACs raises questions about how these technologies are 
regulated now, or should be regulated in the future.  This section will 
explore the possibilities of regulatory responses to the challenges 
posed by new RGBs, from adapting current regulation to the creation 
of a new regulatory institution. 
A. Current Regulation 
1. Federal Regulation of Gene Transfer Research 
Presently, there is no federal law or promulgated regulations 
directly addressing the genetic modification of gametes or early 
embryos, likely because the science supporting genetic modification 
is currently unavailable and regarded as purely speculative.
180
  
However, gene transfer research is subject to federal regulations.
181
  
Some commenters believe germline engineering technologies and 
HACs could fall under the broad definition of “gene transfer” for 
regulatory purposes.
182
  Thus, this section will examine existing 
regulations and discuss whether they apply. 
a. NIH and FDA Oversight 
There are currently only two principal sources of federal 
regulatory oversight of gene-transfer research: the National Institute 
of Health (NIH) and the FDA.
183
  The NIH provides oversight of 
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gene-transfer technologies and funding applications through the 
Recombinant DNA Advisory Committee (RAC) that considers the 
social and ethical implications of “novel gene-transfer research 
protocols that have some funding connection with NIH.”184  Presently, 
the RAC is “responsible for ethical review of all NIH-funded research 
proposals that involve putting genes into human beings, [and] is, as a 
matter of policy, not reviewing any proposals that seek to modify 
gametes or embryos.”185  This decision not to federally fund such 
research has created an effective moratorium, except in cases where 
the research is privately funded.
186
 
The FDA is tasked with monitoring the safety and effectiveness 
of gene-transfer products.  The FDA oversees gene-therapy products 
that are classified as, “any transfer to a human subject . . . that 
introduce[s] genetic material into the body to replace faulty or 
missing genetic material (or to alter the regulation of resident genes) 
for the treatment or cure of disease . . . .”187  Additionally, the FDA 
has asserted authority over gene-therapy products which include 
“biologically based articles, such as a subject’s own cells that have 
been extracted and modified outside the body prior to re-transfer into 
the human subject, or articles (natural or synthetic) that are directly 
transferred to the human subject with the intention of genetically 
altering his or her cells.”188  The FDA’s claim to authority over gene-
therapy products came from a published Federal Registrar Notice in 
1993,
189
 which broadly defined its authority and oversight of gene-
therapy products that, “‘contain genetic materials administered to 
modify or manipulate the expression of genetic material or to alter the 
biological properties of living cells.’  Such products are subject to the 
licensing, false labeling, and misbranding provisions for biologics”190 
under the Public Health Service Act (PHSA)
191
 and drugs under the 
U.S. Federal Food, Drug, and Cosmetic Act (FDCA).
192
  Furthermore, 
because the FDA has potentially classified gene-therapy products as 
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both biologics and drugs, manufacturers would be required to obtain 
both a Biologics License Application (BLA) and a New Drug 
Application (NDA).
193
 
However, the FDA’s scope of authority is limited in the respect 
that it only has authority to regulate claims of safety and effectiveness 
of germline therapy products on human subjects, not the products 
themselves.  The regulations may not legally apply to early embryos 
or gametes that are not considered legal subjects, because human 
subject protections only reach embryos once they are implanted 
through IVF.
194
  The Office of Human Research Protections (OHRP) 
and the FDA under the Common Rule,
195
 protect embryos inside a 
woman’s uterus as human subjects for purposes of research on 
pregnant women and fetuses.
196
  If the regulations did apply, 
presumably the FDA would not approve germline engineering 
technologies or HACs, because such technologies have not been 
proven safe or effective.
197
 
b. Non-governmental Organization (NGO) 
Regulation 
Numerous professional societies and NGOs have issued 
statements in response to emerging genetic engineering and gene-
therapy technologies, including American Association for the 
Advancement of Sciences (AAAS),
198
 which “urged an immediate 
block on a wide range of clinical procedures that the group labeled 
‘inheritable genetic modifications’ (IGM);”199 and the Council for 
Responsible Genetics (CRG), which strongly opposes the use of 
germline gene modification in humans based on scientific, ethical, 
and social concerns.
200
  Other influential NGOs include the American 
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 200. See Council for Responsible Genetics, Position Paper on Human Germline 
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Medical Association (AMA), which has stated that “genetic 
engineering should be conducted safely, no dangerous viruses should 
be employed, and the safety and effectiveness of any such procedures 
should be evaluated very closely.”201  Analogous to the CRG’s 
response to genetic engineering, the AMA asserts that germline 
modification should not be explored because of the “‘welfare of 
future generations and its association with risks and potential for 
unpredictable and irreversible results.’  Nontherapeutic applications 
of gene-transfer are ‘contrary to the ethical traditions of medicine and 
against the egalitarian values of society.’”202  While professional 
societies do not have formal regulatory authority, their influence on 
constituencies and policy makers could have a significant impact on 
how current and future genetic engineering legislation is perceived 
and directed by the general public. 
B. Future Regulation 
Once RGBs become feasible, or nearly so, the public may 
demand a legislative or regulatory response.  This section will 
consider four possible policy options. 
1. Congress Bans Reproductive Genetic Biotechnologies 
(RGBs) 
First, those who oppose germline engineering on religious, 
moral, or policy grounds might urge Congress to impose a legislative 
ban on all pertinent technologies.  However, such a ban will likely be 
ineffective for several reasons.  There are hundreds of fertility clinics 
in the United States.  These clinics, and the labs associated with them, 
offer IVF and related technologies to thousands of clients every day.  
Doctors harvest eggs and sperm; labs use those gametes to create 
embryos; and doctors then transfer embryos back into the wombs of 
women who are anxious to become parents.  Throughout all of this 
activity, medical privacy reigns supreme.  In such a setting, it would 
be easy for physicians to employ unauthorized RGB procedures to 
alter the gametes or embryos with desired genetic modifications, 
 
Manipulation, COUNCIL FOR RESPONSIBLE GENETICS [hereinafter Human Germline 
Manipulation], available at 
http://www.councilforresponsiblegenetics.org/ViewPage.aspx?pageId=101# (last visited Oct. 2, 
2013). 
 201. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 113; see also Human 
Germline Manipulation, supra note 200, at 118. 
 202. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 111-13. 
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under the pretense of a normal IVF procedure.
203
  As a result, the only 
effective way to ban such a practice, would be to ban both therapeutic 
and enhancement procedures.
204
 
Moreover, even if RGBs were illegal within the United States, 
parents could simply travel to other countries with laxer laws, 
undergo IVF with RGBs, and return to the United States to birth the 
genetically modified child.
205
  Such a scenario would likely be too 
burdensome for the U.S. to regulate or enforce, because it would 
require a controversial determination of whether or not a child has 
been illegally enhanced.  In addition, law enforcement would need to 
establish specific criteria and consequences for illegal “therapy” or 
“enhancement,” and under what circumstances children would be 
subject to mandatory genetic testing.
206
  Creating such an elaborate 
enforcement scheme would likely prove a complete ban unrealistic, 
especially if the enhancement would create a social benefit for both 
the individual and society.
207
 
Furthermore, enforcing this Federal-funding ban will likely 
prove ineffective, as researchers continue to cross thresholds 
previously considered off limits, by replacing human mitochondrial 
DNA in embryos to avoid gene mutations that could be epigenetically 
passed onto the next generation.
208
  A similar technique, called 
ooplasm transfer
209
 has produced, to date, thirty children born 
worldwide, but it has not been approved for clinical testing within the 
United States.
210
  Therefore, for practical reasons, a future ban on 
 
 203. See Mehlman, supra note 21, at 564-65 (“The FDA presently has no authority to 
control the prescribing behavior of physicians.  Consequently, they are free to prescribe products 
for unauthorized uses.”). 
 204. See id.; see also STOCK, supra note 3, at 153; About Us, EDITAS MEDICINE, 
http://editasmedicine.com/about.php (last visited Feb. 25, 2014) (“The company’s mission is to 
translate its genome editing technology into a novel class of human therapeutics that enable 
precise and corrective molecular modification to treat the underlying cause of a broad range of 
diseases at the genetic level.”). 
 205. But see George J. Annas et al., Protecting the Endangered Human: Toward an 
International Treaty Prohibiting Cloning and Inheritable Alterations, 28 AM. J.L. & MED. 151, 
154 (2002). 
 206. See Mehlman, supra note 21, at 565-68. 
 207. See id. at 565-70. 
 208. See Masahito Tachibana et al., Towards Germline Gene Therapy of Inherited 
Mitochondrial Diseases, 493 NATURE 627 (2012), available at 
http://dx.doi.org/10.1038/nature11647. 
 209. See Kerry L. Macintosh, Brave New Eugenics: Regulating Assisted Reproductive 
Technologies in the Name of Better Babies, 2010 U. ILL. J.L. TECH. & POL’Y 257, 271 (2010). 
 210. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 28, 34; see Jason A. 
Barritt et al., Cytoplasmic Transfer in Assisted Reproduction, 7 HUM. REPROD. UPDATE 428, 
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RGBs may prove ineffective. 
2. Congress Augments the Regulatory Authority of the 
FDA 
Second, proponents of germline engineering have proposed that 
Congress might enact legislation to expand the scope of the FDA’s 
authority to cover RGBs.  The advantage of this approach is that the 
FDA already exists and (arguably) is ready to exercise oversight, at 
least on safety and efficacy grounds.
211
  However, the FDA’s existing 
patterns of activity do not regulate RGBs, but rather “drugs, devices, 
and biologics that are or will be marketed for use in the United States.  
Its principal purpose is to ensure the safety and efficacy of products 
according to their approved use.”212  Therefore, in order for the FDA 
to expand its jurisdiction to include RGBs, “it might be necessary for 
the FDA to construe an embryo that might be transferred into a uterus 
as a ‘drug,’ ‘biological product,’ or ‘device.’”213  Classifying future 
genetic engineering technologies under the FDA’s definitions of 
drugs, biologics, or devices will likely present regulatory challenges, 
because each definition carries its own regulatory frameworks that 
would require a statutory amendment to define a modified human 
embryo as a “product.”214  If Congress fails to ban RGBs, the FDA 
will most likely continue to provide regulatory authority over ARTs 
and future RGBs, under the auspices of these definitions, as it already 
understands the complex challenges involved in exercising 
jurisdiction over these broad definitions.
215
  Furthermore, the FDA’s 
unique position distinctively qualifies it to undertake the daunting 
responsibility of creating regulatory policies and guidelines that 
 
428-34 (2001). 
 211. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 188 (The FDA regulates a 
broad range of consumer products under the Food, Drug, and Cosmetic Act (FDCA), and the 
Public Health Services Act (PHSA)). 
 212. Id. at 55; see generally Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 301 (West 
2014); Public Health Services Act, 42 U.S.C. § 201 (West 2014). 
 213. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 61. 
 214. See Elizabeth C. Price, Does the FDA Have Authority to Regulate Human Cloning?, 
11 HARV. J. L. & TECH. 619, 638-41 (1998) (arguing the FDA does not have the statutory 
authority to regulate embryos as biological products for human cloning). 
 215. See id. at 55; cf. FRANCIS FUKUYAMA & FRANCO FURGER, BEYOND BIOETHICS: A 
PROPOSAL FOR MODERNIZING THE REGULATION OF HUMAN BIOTECHNOLOGIES 231 (2006) 
(“Even assuming that by some obscure legal theory the FDA does have the power the adjudicate 
contentious ethical questions – i.e., to regulate the use of new reproductive technologies and 
biomedical research not exclusively in terms of safety and efficacy – it would be unsuitable for 
this task.”). 
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would support successful future regulation of RGBs.
216
  The 
following three classifications: (i) drugs, (ii) biologics, and (iii) 
devices, are briefly discussed as potential classifications the FDA 
could expand to include RGBs within its jurisdiction. 
a. Drugs 
The FDA could exercise its jurisdiction over RGBs under the 
broad statutory definition of “drug” which is defined according to the 
Food, Drug, and Cosmetic Act (FDCA), as “encompassing any 
officially recognized article that is either (1) intended for use in the 
diagnosis, cure, mitigation, treatment, or prevention of disease in 
man, or (2) (excepting foods) intended to affect the structure or any 
function of the body of man.”217  The definition of a drug or dietary 
supplement under the FDA currently categorizes pharmaceutical 
products, or off-label products, which are subject to premarket 
authorization.  However, classifying RGBs as drugs likely 
encompasses too broad of a definition and offers inadequate 
regulation for a drug that would change the structure and function of 
the human body.
218
 
b. Biological Products 
The FDA under the PHSA has the regulatory authority to 
regulate “biological products,” defined as “‘any virus, therapeutic 
serum, toxin, anti-toxin, vaccine, blood, blood component or 
derivative, allergenic product or analogous product, applicable to the 
prevention, treatment or cure of diseases or injuries to humans.’”219  
Similarly, an Investigational New Drug Application (IND) required 
for drugs, and biologics must also undergo an approval process 
through a Biologics License Application (BLA), which requires the 
product be “safe, pure, and potent.”220  In addition, under the FDA’s 
authority to regulate biological products, it oversees the Center for 
Biologics Evaluation and Research (CBER), which has “undertaken 
 
 216. See Christine Willgoos, FDA Regulation: An Answer to the Questions of Human 
Cloning and Germline Gene Therapy, 27 AM. J.L. & MED. 101, 119-24 (2001) (“[T]he FDA 
appears to be a good candidate for the oversight of genetically manipulated reproductive 
technology.”). 
 217. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 55-56. 
 218. See JULIAN SAVULESCU ET AL., supra note 11, at 511. 
 219. REPRODUCTION AND RESPONSIBILITY, supra note 5, at 56 (citing 42 U.S.C. § 262(i) 
(West 2014)). 
 220. Id. at 57. 
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regulation of cellular and gene-therapy products,” 221 which must 
meet the same pre-market standards for safety as drugs.  Therefore, 
the FDA could potentially encompass future gene-modification RGB 
products under a strained biologic definition, but such a classification 
for enhancement may not be suitable. 
c. Devices 
According to the FDA, the products that are subject to premarket 
authorization include drugs, biological products, food additives, and 
devices that the FDA reviews on a product-by-product basis, and 
“determines whether the proposed device is substantially equivalent 
to a product that is already on the market.”222  Similar to the definition 
of “drug” and “biological product” discussed earlier, a “device” is 
defined as any “‘instrument, apparatus, implement, machine, 
contrivance, implant, in vitro reagent, or other similar related article, 
including any component’ that is officially recognized, intended for 
the diagnosis, treatment, cure, mitigation, or prevention of disease in 
man, or intended to affect the structure and function of the body.”223  
The FDA reviewers often require manufactures to provide product 
related scientific research data and detailed product information when 
submitting a product to the FDA in order to support their regulatory 
decisions—those presenting greater safety risks such as RGBs would 
likely be subject to a more rigorous pre-market approval process for 
safety and effectiveness.
224
  However, because the FDA’s regulatory 
authority only regulates products and claims about products, not the 
technologies themselves; the FDA may not be aware of the 
unsanctioned use of RGBs on the market, a safety problem perceived 
by many as a serious regulatory inadequacy.
225
  However, looking at 
how medical devices are currently regulated and examining their 
efficacy under the FDA’s FDCA may help illustrate the FDA’s ability 
to adequately regulate RGBs as medical devices, rather than drugs, or 
biologics now and in the future.  Devices are regulated in a tiered 
three level classification system that is based on the relative degree of 
risk associated with the product:
226
 Class I or II devices are 
 
 221. Id. 
 222. Id. at 59. 
 223. Id. at 58. 
 224. Id. at 59. 
 225. See Robertson, supra note 16, at 483; see also Mehlman, supra note 21, at 564-66 
(suggesting the DEA rather then the FDA may be the most appropriate government agency to 
regulate genetic enhancements). 
 226. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 59. 
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considered low risk in which the safety and effectiveness are well 
established; Class III devices are the most complex and significantly 
high-risk devices used to sustain or support life, or those implanted in 
the human body.
227
  Therefore, although the FDA’s definition of 
devices could likely incorporate future RGBs as Class III devices, 
Congress would be required to augment the FDA’s regulatory 
authority beyond its current classification system to adequately 
consider the moral concerns of RGBs. 
3. Congress Creates a New Independent Regulatory 
Agency 
Third, Congress could enact legislation authorizing the creation 
of a new regulatory agency focused specifically on the oversight of 
genetic engineering biotechnologies.  This ambitious task would 
require the new agency to be more competent than the FDA to deal 
with the complex array of social, ethical, and legal issues.  In practice, 
this new independent agency could more effectively decrease 
bureaucracy currently existing between multiple agencies claiming 
authority, and provide unified regulatory guidance for research and 
development funding requirements.
228
  Traditionally Congress has 
established independent regulatory agencies to oversee specific 
policy-making areas that require extensive expertise and judgment, 
and provide isolation from political considerations.
229
  Currently, 
many of the emerging issues discussed in assisted reproduction, 
genetic engineering, and RGBs are new and unprecedented, and do 
not fall naturally into the jurisdiction of any existing government 
body or agency.
230
  This new agency could be authorized to directly 
consider policy concerns that extend beyond the FDA’s purview of 
safety and efficacy. 
Initially, a new agency tasked with regulatory authority over 
genetic engineering technologies, would need to be cautious not to 
expand its authority to include differentiating biotechnologies as 
either therapy or enhancement.  Granting such authority to 
differentiate between the approval of technologies for therapy and not 
enhancement purposes, could grant this new governmental regulatory 
agency an effective monopoly over which future biological traits of 
its citizens are acceptable; a fear shared by many opponents of IGM 
 
 227. See id. 
 228. See FUKUYAMA, supra note 7, at 215. 
 229. See FUKUYAMA & FURGER, supra note 215, at 293-311. 
 230. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 187. 
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as a method of eugenics.
231
  Opponents such as Fukuyama argue that 
the “FDA [or a new agency] is not set up to make politically sensitive 
decisions concerning the point at which selection for characteristics 
like intelligence and height ceases to be therapeutic and becomes 
enhancing, or whether these characteristics can be considered 
therapeutic at all.”232 
Other nations have already created independent agencies to 
address these challenges such as: the Human Fertilization and 
Embryology Authority (HFEA) in Britain, and the Assisted Human 
Reproduction Agency (AHRA) in Canada.
233
  In response, some 
commenters have suggested that the creation of a new regulatory 
agency would likely resemble Britain’s HFEA,234 and would act with 
its new federal authority to place greater restrictions on RGBs.
235
  
However, a new regulatory agency could potentially accelerate future 
research and development of RGBs, if national attention and focus is 
brought to the issue through a national conversation that has 
previously remained largely inaccessible to the general public.
236
  
Furthermore, creation of an independent agency may be more adept at 
handling the complex policies required of RGBs, but it could 
arguably lead to more restrictive regulation if political conflicts over 
embryo status, federal research funding, and abortion rights shift the 
focus of its purpose.
237
  As several commenters have suggested, if left 
to free-market forces, “[m]ost regulation will occur informally 
through the market interactions of willing consumers and providers of 
these services against a background of common law norms, some 
professional self-regulation, and occasional state legislative 
intrusions.”238  Therefore, Congress could decide to give the FDA the 
power to consider moral and philosophical issues of RGBs, thereby 
 
 231. See Mehlman, supra note 21, at 556-57. 
 232. FUKUYAMA, supra note 7, at 213. 
 233. See REPRODUCTION AND RESPONSIBILITY, supra note 5, at 187; FUKUYAMA & 
FURGER, supra note 215, at 149-79. 
 234. See Letter from the Center for Genetics and Society addressing HFEA’s current 
consultation on Mitochondrial Replacement Research (Nov. 15, 2012) (The HFEA launched a 
public consultation to gather views on the social and ethical impact of mitochondria replacement 
techniques. In response the CRG sent a letter to the HFEA, strongly recommending that the 
current UK law prohibiting germline engineering remain in effect), available at 
http://www.biopoliticaltimes.org/downloads/Letter%20to%20HFEA.pdf. 
 235. See Robertson, supra note 16, at 482-84; see also REPRODUCTION AND 
RESPONSIBILITY, supra note 5, at 187. 
 236. See generally FRANKEL & CHAPMAN, supra note 68. 
 237. See Robertson, supra note 16, at 482; see also, Macintosh, supra note 209, at 292-93. 
 238. See Robertson, supra note 16, at 483-84. 
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expanding its regulatory authority without having to distort its current 
three-tier classifications.  However, such a radical change would 
require reorganization of the agency and its staffers to address the 
emerging social, ethical, and philosophical issues of RGBs.  If those 
elements were to be considered by the FDA, it would make more 
sense for Congress to focus its resources on creating a new 
independent agency and framework for oversight with new staffers 
that have the relevant expertise.
239
  This new agency should be tasked 
with promoting a national conversation about the acceptable uses of 
RGBs for therapeutic and enhancement applications, designing 
mechanisms for assessing the social, ethical, and safety risks 
involved, encouraging the creation of public and private policy 
guidelines, and serving as a single data repository and funding 
recommendation mechanism for genetic research on animals and 
humans.
240
  An agency tasked with these responsibilities and 
regulatory authority would be able to adequately perform independent 
scientific and ethical reviews of all RGB research protocols and 
procedures.
241
 
CONCLUSION 
As the biotechnology revolution increases humankind’s genomic 
knowledge, our current abilities using ARTs, and the future 
possibilities of RGBs, the bioethical, legal, and social challenges of 
choosing our children’s genes will require comprehensive policy 
frameworks and regulatory oversight of these technologies to ensure 
their safe and effective development.  Public awareness and attitudes 
of genetic engineering will influence its evolution, and public policy 
needs to adapt with unique regulations that consider the greater social 
and moral implications.  Scientific advancements may provide the 
opportunity to fundamentally alter our evolution and biological 
potential as a species by rejecting the archaic practice of random 
genetic variation through sexual reproduction and natural selection.  
However, before we adopt RGBs that go beyond therapy for 
enhancement of our bodies and our minds, we must promote equality 
and fairness; otherwise we risk potential social and economic 
 
 239. See FRANKEL & CHAPMAN, supra note 32, at 51. 
 240. See id. at 51-53. 
 241. See id.; FUKUYAMA & FURGER, supra note 215, at 297-98 (“This organizational form 
is a far better match for what may be described as the two main tasks facing a regulatory agency 
responsible for overseeing reproductive medicine and biomedical research – implementing the 
Congressional mandate and adjudicating societal disputes – than an executive agency.”). 
KELLY 4/2/2014  11:02 PM 
2014] CHOOSING THE GENETICS OF OUR CHILDREN 347 
instability where genetic discrimination fragments society into a 
genetic aristocracy.  Rather than continuing to place federal-funding 
restrictions on technological advances in genetic engineering, 
policymakers need to recognize such economic mechanisms or 
temporary bans will likely prove ineffective, and need to be 
reconsidered.  One such proposed solution for policymakers is the 
creation of a new independent regulatory agency tasked specifically 
to address these issues, rather than attempting to augment the FDA’s 
existing policy framework and statutory definitions to meet the needs 
of these emerging challenges.  The creation of a new regulatory 
agency would appropriately balance arguments advanced by both 
proponents and opponents of genetic engineering technologies used in 
assisted reproduction.  Its creation would support the responsible and 
safe adoption of RGBs to increase human prosperity, while 
simultaneously providing adequate regulatory oversight, and 
enforcement mechanisms if parents one day decide to choose the 
genetics of their children. 
 
